Eradivir’s founder, Dr. Philip S. Low, has successfully developed multiple FDA-approved targeted small molecules. These therapies all function by attaching various payloads to ligands, which bind with high specificity to diseased cells. Examples of approved molecules include a radiotherapy drug for prostate cancer and an intraoperative imaging agent for lung and ovarian cancers. Several others are currently in clinical trials (e.g., treatments for cancer, malaria, and sickle cell anemia). Eradivir was founded in March 2020 to advance a promising application of this platform in combating multiple disease states, initially focusing on influenza and other respiratory infections.
Eradivir的外部链接
US，IN，West Lafayette
Eradivir Scientist Dr. Imrul Shahriar recently appeared on BBC's Science in Action podcast to discuss Eradivir's groundbreaking strategies for treating influenza. Check out the full episode here: https://lnkd.in/dp3e6Hy9
Eradivir is pleased to announce a successful Series A funding round for Phase 2a clinical trials in Influenza. See the full story here:
Eradivir has completed the required preclinical studies for its influenza drug EV25 and will seek regulatory approval to dose volunteers in Belgium by the end of the year